Theriva Biologics (TOVX) Capital Expenditures (2010 - 2025)

Theriva Biologics (TOVX) posted quarterly Capital Expenditures of $19000.0 for Q3 2025, down 66.07% quarter-over-quarter from $56000.0 in Q4 2023.

Theriva Biologics (TOVX) Capital Expenditures (2010 - 2025) Analysis & Trends

Theriva Biologics (TOVX) has reported Capital Expenditures for 13 consecutive years, with $19000.0 the latest figure, recorded in Q3 2025.

In Q3 2025, Capital Expenditures changed N/A year-over-year to $19000.0; the TTM figure through Dec 2025 stood at $19000.0 (down 89.73% YoY), while the FY2025 annual figure was $35000.0, up 3400.0% from the prior year.
Capital Expenditures declined to $19000.0 in Q3 2025 per TOVX's latest filing, from $56000.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $129000.0 in Q3 2023 and bottomed at $8000.0 in Q1 2023.
Historically, Capital Expenditures has averaged $39000.0 across 4 years, with a median of $14000.0 in 2021.
On a YoY basis, Capital Expenditures climbed as much as 1072.73% in 2023 and fell as far as 38.46% in 2023.
Theriva Biologics' Capital Expenditures stood at $14000.0 in 2021, then surged by 550.0% to $91000.0 in 2022, then slumped by 38.46% to $56000.0 in 2023, then tumbled by 66.07% to $19000.0 in 2025.
Business Quant data shows TOVX's Capital Expenditures at $19000.0 in Q3 2025, $56000.0 in Q4 2023, and $129000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	Theriva Biologics	10.64 Mn	10.64 Mn	-	-

Download Data